Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maha Hussain

Showing results (91-100 of 213) with videos related to

Pageof 22
Sort By:
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
Clinical Genitourinary Cancer|October 19, 2015
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate CancerMark N Stein, Maha Hussain, Walter M Stadler, et al.
JCI Insight|November 24, 2025
Targeting p300 and CBP abolishes HOXB13-loss-induced lipogenesis and tumor metastasisXiaodong Lu, Liu Peng, Qi Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With EnzalutamideAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Molecular Medicine (Cambridge, Mass.)|October 30, 2013
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancerPetros D Grivas, Kathleen C Day, Andreas Karatsinides, et al.
Nutrition and Cancer|October 12, 2007
Lycopene and soy isoflavones in the treatment of prostate cancerUlka Vaishampayan, Maha Hussain, Mousumi Banerjee, et al.
JAMA Oncology|January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate CancerDawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Future Oncology (London, England)|August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2026
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trialBertrand Tombal, Maha Hussain, Fred Saad, et al.
Cancer|November 14, 2007
Randomized clinical trial of a family intervention for prostate cancer patients and their spousesLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Pageof 22

Showing results (91-100 of 213) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
Clinical Genitourinary Cancer|October 19, 2015
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate CancerMark N Stein, Maha Hussain, Walter M Stadler, et al.
JCI Insight|November 24, 2025
Targeting p300 and CBP abolishes HOXB13-loss-induced lipogenesis and tumor metastasisXiaodong Lu, Liu Peng, Qi Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With EnzalutamideAndrew J Armstrong, Arun A Azad, Taro Iguchi, et al.
Molecular Medicine (Cambridge, Mass.)|October 30, 2013
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancerPetros D Grivas, Kathleen C Day, Andreas Karatsinides, et al.
Nutrition and Cancer|October 12, 2007
Lycopene and soy isoflavones in the treatment of prostate cancerUlka Vaishampayan, Maha Hussain, Mousumi Banerjee, et al.
JAMA Oncology|January 1, 2016
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate CancerDawn L Hershman, Joseph M Unger, Jason D Wright, et al.
Future Oncology (London, England)|August 16, 2023
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?Maha Hussain, Cora N Sternberg, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|April 12, 2026
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trialBertrand Tombal, Maha Hussain, Fred Saad, et al.
Cancer|November 14, 2007
Randomized clinical trial of a family intervention for prostate cancer patients and their spousesLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Pageof 22